On February 4, 2026, Spyre Therapeutics (SYRE) disclosed two insider trading transactions. Director Turtle Cameron sold 15,700 shares on February 2, 2026.
[Recent Insider Transactions]
Disclosure Date
Position
Name
Transaction Date
Buy/Sell
Quantity
Price per Share/USD
Total Amount/USD
February 4, 2026
Director
Turtle Cameron
February 2, 2026
Sell
957
31.82
30,500
February 4, 2026
Director
Turtle Cameron
February 2, 2026
Sell
14,000
32.87
461,600
January 6, 2026
Director
Turtle Cameron
January 2, 2026
Sell
2,191
31.79
69,700
January 6, 2026
Director
Turtle Cameron
January 2, 2026
Sell
12,700
30.47
387,200
January 6, 2026
Director
Turtle Cameron
January 2, 2026
Sell
100
32.39
3,239
December 3, 2025
Director
Turtle Cameron
December 1, 2025
Sell
4,005
29.83
119,500
December 3, 2025
Director
Turtle Cameron
December 1, 2025
Sell
11,000
28.73
315,900
November 5, 2025
Director
Turtle Cameron
November 3, 2025
Sell
16,800
23.66
398,600
November 5, 2025
Director
Turtle Cameron
November 3, 2025
Sell
28,200
23.13
651,200
September 3, 2025
Executive
Burrows Scott L
September 2, 2025
Sell
18,400
16.26
299,600
[Company Information]
Spyre Therapeutics, Inc. was converted from a Delaware LLC on December 16, 2013. The company is a biotechnology firm focused on creating next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre’s product line includes long-acting antibodies targeting α4β7, TL1A, and IL-23.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
US Stock Insider Trading | Spyre Therapeutics disclosed two insider trading transactions on February 4
On February 4, 2026, Spyre Therapeutics (SYRE) disclosed two insider trading transactions. Director Turtle Cameron sold 15,700 shares on February 2, 2026.
[Recent Insider Transactions]
[Company Information]
Spyre Therapeutics, Inc. was converted from a Delaware LLC on December 16, 2013. The company is a biotechnology firm focused on creating next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre’s product line includes long-acting antibodies targeting α4β7, TL1A, and IL-23.